A June inspection now has the FDA hitting Dr. | The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-June inspection.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The U.S. FDA issues seven observations to Dr. Reddy's Hyderabad biologics facility following a pre-licence inspection.
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares are among the seven…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the…
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery…
